Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous subcutaneous flumazenil infusion for high-dose benzodiazepine dependence
NL-OMON41934Phase 2Recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Feb 2017
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of flumazenil in benzodiazepine dependence, sponsored by Radboud University Medical Center. Primary endpoints: Subjective Withdrawal Scale, Objective Withdrawal Scale and 3 more. Started Feb 2017; status: recruiting.
02
Drugs
flumazenil
03
Conditions
benzodiazepine dependence
Beyond the preview
Go deeper on NL-OMON41934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41934.